API CAS 1009119-64-5 Daclatasvir Pharmaceutical Daclatasvir Powder Daclatasvir

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Adult
• State: Powder
• Purity: >99%
• Model NO.: D-sung-Daclatasvir
• Product Name: Daclatasvir
• Name: Daclatasvir Powder
• Appearance: White Powder
• Color: White Color
• Grade: Pharmaceutical Garde
• Assay: HPLC 99%
• Application: Anthelmintics
• Specific: COA
• Test Method: HPLC, UV
• Shelf Life: 2 Years
• CAS No.: 1009119-65-6
• Mf: C40h50n8o6
• MW: 738.88
• Boiling Point: 1071.2-65.0
• Density: 1.249
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-Sung
• Origin: Xi′an Shaanxi
• Production Capacity: 1000kg/Month

Product Description

API CAS 1009119-64-5 Daclatasvir Pharmaceutical Daclatasvir Powder Daclatasvir

Product Description

Product Details

Product Name	Daclatasvir
Appearance	White Powder
CAS No.	1009119-65-6
MF	C40H50N8O6

Daclatasvir is a direct-acting antiviral agent against Hepatitis C Virus (HCV) used for the treatment of chronic HCV genotype 1 and 3 infection.Hepatitis C is an infectious liver disease caused by infection with Hepatitis C Virus (HCV). 
Daclatasvir was discovered as a first-in-class inhibitor of the non-structural viral protein 5A (NS5A), a phosphoprotein that
plays an important role in hepatitis C replication.

Application&Function

Daclatasvir (Daklinza) has obtained "priority review" status, combined with sorafenib for the treatment of genotype III adult patients with chronic hepatitis C. Daklinza has been the first drug that has been proved of being effective in the treatment of genotype III hepatitis C virus infection without the co-administration with interferon or ribavirin. Interferon and ribavirin are two drugs approved by FDA for the treatment of hepatitis C virus infection. Hepatitis C is a viral disease that can cause inflammation of the liver, resulting in decreased liver function or liver failure. Most patients infected with hepatitis C have no symptoms until liver damage becomes apparent, which may take several years.
Globally, genotype III hepatitis C is the second most common genotype of hepatitis C after genotype 1 hepatitis C and is considered to be one of the most refractory genotype diseases. Daklinza is a pan-genotype NS5A replication complex inhibitor, with efficacy of inhibition of RNA replication and viral assembly, dual antiviral effect.

Specification